Pharvaris N.V.

Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases. The company is headquartered in Leiden, the Netherlands, and also operates in Switzerland and the United States. It was established in 2015 by a team of experienced biopharmaceutical professionals with a shared vision to develop innovative therapies for rare diseases.

The company’s lead product, PHA121, is a small molecule bradykinin B2-receptor antagonist that is currently in Phase II clinical trial for the treatment of hereditary angioedema (HAE). In addition, Pharvaris is developing PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks, which is in Phase 2 clinical trial, and PHVS719, a prophylactic extended-release tablet for HAE patients, which is in Phase 1 clinical trial.

Pharvaris is committed to advancing treatments for rare diseases and has established collaborations with leading research institutions and patient advocacy organizations to support its development efforts. The company has also established strategic partnerships with a number of leading pharmaceutical companies, including Roche, Novartis, and Pfizer, to help accelerate the development of its products.